Trials of donanemab have shown its potential in slowing progress of early-stage Alzheimer's disease
Professor Dame Pamela Shaw joins to help advance development of its ALS/MND drug candidate SAM001
NR Times reports on the much-anticipated trial of ALS treatment AMX0035, in an interview with Machelle Manuel, head of global medical affairs at its creator Amylyx. Recently...
Epstein-Barr Virus found to be a leading cause of Multiple Sclerosis (MS)
NR Times meets Coya Therapeutics’ founder and CEO Howard Berman as he closes in on his mission to halt ALS / motor neurone disease and other...
Study will look into existing drugs and how they could slow or stop disability worsening in people with MS
TOP HAT study examines its potential in reducing hallucinations
New research reveals the potential of the drug terazosin in supporting those with motor neuron disease
'Our study is an important step on the way for rituximab to become an approved MS drug' say researchers
A novel staging framework that assesses the progression of HD has been developed